Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Marty R who wrote (3011)	4/12/2000 10:58:00 PM
From: Chi Wong	Read Replies (1) \| Respond to of 5665

Here's more rehash. Mostly for myself, but what the hell. From Mitch's Message: "We are working very hard to conclude an arrangement with one or more third parties" [I believe IMGN has been saying this longer than I've held shares so why am I restating it? Why is he restating it?] "I believe one of the real growth potentials for ImmunoGen is to collaborate with the sponsors of new antibodies under development, to use our effector molecule technology to transform a naked antibody into an effective anti-cancer agent. I believe that this is ImmunoGen's near-term future--to let others use our effector molecule know-how as an enabling technology to create new and effective products. " [near term. I interpret this as IMGN's area of greatest potential because they gave away HuC242 to get the tech platform in the clinic.... many longs think efficacy is what's important, but really IMGN is more interested in showing that it's tech platform is effective so everyone else can line up to use the technology] Alas, the recent failure of VPHM is a reminder to keep off those blinders because no matter how positive we feel about this company, you can never know what cards will be dealt tomorrow.